Fresenius Medical Care Announces Update on Dialysate Concentrate Products
ID: 782593
Fresenius Medical Care Announces Update on Dialysate Concentrate Products
Ben Lipps, chief executive officer of Fresenius Medical Care, commented: "We have commented many times on our pride in our global team?s commitment to quality. One has to understand the nature of the medical status that influences the acid/base balance in dialysis patients. The company?s actions related to these products were appropriate and responsible. Both products are safe and effective and were reviewed and cleared by the Food and Drug Administration several years ago. I am confident of our position on this medical issue?.
On December 7, 2012, FMCNA received a subpoena from the United States Attorney for the District of Massachusetts requesting production of a range of documents relating to products manufactured by FMCNA. FMCNA intends to cooperate fully in this matter.Fresenius Medical Care is the world's largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 2.1 million individuals worldwide. Through its network of 3,135 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatment to 256,521 patients around the globe. Fresenius Medical Care is also the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products.
For more information about Fresenius Medical Care, visit the Company?s website at www.fmc-ag.com.
Disclaimer
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.
Matthias Link
Corporate Communications
Fresenius Medical Care
Else-Kröner-Straße 1
61352 Bad Homburg
Germany
T +49 6172 609-2872
F +49 6172 609-2294
matthias.link@fresenius.com
www.fmc-ag.com
PresseKontakt / Agentur:
Matthias Link
Corporate Communications
Fresenius Medical Care
Else-Kröner-Straße 1
61352 Bad Homburg
Germany
T +49 6172 609-2872
F +49 6172 609-2294
matthias.link(at)fresenius.com
www.fmc-ag.com
Datum: 13.12.2012 - 09:51 Uhr
Sprache: Deutsch
News-ID 782593
Anzahl Zeichen: 3663
pressrelations.de – ihr Partner für die Veröffentlichung von Pressemitteilungen und Presseterminen, Medienbeobachtung und Medienresonanzanalysen
Diese Pressemitteilung wurde bisher 358 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Fresenius Medical Care Announces Update on Dialysate Concentrate Products"
steht unter der journalistisch-redaktionellen Verantwortung von
Fresenius Medical Care (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
